Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Elderly and women have been often under-represented in randomised clinical trials testing the effect of treatments on cardiovascular diseases even though these diseases highly affect both of them.
Compared to their younger counterparts elderly have a higher incidence of disease-related morbidities, take more medicines and account for more adverse drug-related events. Similarly women present several differences in pathophysiology, clinical manifestations and outcomes in comparison to their male counterparts. For these reasons the results of randomised clinical trials obtained in younger men cannot be simply translated in elderly and women and the conduction of research and clinical trials in these patient populations is a key aspect to acquire evidence-based knowledge in the understanding and management of their conditions and treatment.
Although the under-representation of elderly and women has been discussed for several years and several international guidelines or recommendation have been published to suggest how to improve the recruitment of these two populations, their recruitment is still insufficient. In particular, frail elderly and those with co-morbidities are not included questioning the external validity and the safety of most treatments.
Aim of this review is to critically analyse how current recommendations for treatments of cardiovascular disease are not adequately devised for elderly and women.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Neugarten B. Middle age and aging. Chicago and London: The University of Chicago Press; 1968.
Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4(2):112–21. PubMed
Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the QT interval: a review. J Womens Health (Larchmt). 2012;21(9):933–41. CrossRef
Maas AH, van der Schouw YT, Regitz-Zagrosek V, Swahn E, Appelman YE, Pasterkamp G, et al. Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J. 2011;32(11):1362–8. CrossRefPubMed
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.
Serra V, Watson J, Sinclair D, Kneale D. Living beyond 100: a report on centenarians. London: International Longevity Centre; 2011.
Bugental DB, Hehman JA. Ageism: a review of research and policy implications. Soc Issues Policy Rev. 2007;1(1):173–216. CrossRef
Nair BR. Evidence based medicine for older people: available, accessible, acceptable, adaptable? Aust J Ageing. 2002;21:58–60. CrossRef
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;2(136):161–7. CrossRef
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016. doi: 10.1177/2047487316653709.
- Are elderly and women under-represented in cardiovascular clinical trials? Implication for treatment
MD, PhD Cristiana Vitale
MD, PhD, FACC Giuseppe Rosano
MD Massimo Fini
- Springer Vienna